Verrica Pharmaceuticals, which is developing a drug-device that administers cantharidin for warts and skin diseases, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.
The West Chester, PA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol VRCA. Verrica Pharmaceuticals filed confidentially on March 30, 2018. BofA Merrill Lynch, Jefferies and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
